Markets:

Overview

News

Currencies

International

Treasuries

Xenon Pharmaceuticals Inc. - Common Shares (NQ:XENE)

56.76 -0.09 (-0.17%)

Streaming Delayed Price Updated: 11:48 AM EDT, Apr 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Xenon Pharmaceuticals Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >

Xenon's Epilepsy Candidate Rapidly Reduces Focal Onset Seizure Frequency ↗

June 23, 2022

Via Benzinga

US Stock Futures Mixed Ahead Of Jobless Claims, Powell Testimony ↗

June 23, 2022

Pre-open movers

Via Benzinga

Xenon Pharmaceuticals Shares Drop On Proposed Public Offering ↗

June 22, 2022

Via Benzinga

Recap of Tuesday's Biotech Catalysts - End of the Day Summary ↗

June 21, 2022

Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid...

Via Benzinga

Looking Into Xenon Pharmaceuticals's Return On Capital Employed ↗

June 13, 2022

According to Benzinga Pro data, during Q1, Xenon Pharmaceuticals (NASDAQ:XENE) posted sales of $8.77 million. Earnings were up 23.06%, but Xenon Pharmaceuticals still reported an overall loss of $19.67...

Via Benzinga

Recap: Xenon Pharmaceuticals Q1 Earnings ↗

May 10, 2022

Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Scheduled For March 1, 2022 ↗

March 01, 2022

Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...

Via Benzinga

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗

May 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Swing Trading Stock Watchlist For April 11 And Beyond ↗

April 10, 2022

The stock market's health is neutral. It is not bad, but it is not great either. I’m willing to take long trades in the stocks discussed if they form valid trade setups and trigger, but I’m not being...

Via Talk Markets

Swing Trading Stock Watchlist For April 4 And Beyond ↗

April 03, 2022

The stock market's health has improved. That means I have the green light to buy stocks that are forming quality trade setups. Let's dive into what I have been looking at this week.

Via Talk Markets

Earnings Scheduled For May 10, 2022 ↗

May 10, 2022

Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.

Via Benzinga

Xenon Pharmaceuticals's Return On Capital Employed Overview ↗

March 07, 2022

Xenon Pharmaceuticals (NASDAQ:XENE) brought in sales totaling $3.74 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 65.52%, resulting in...

Via Benzinga

Recap: Xenon Pharmaceuticals Q4 Earnings ↗

March 01, 2022

Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

Xenon Pharmaceuticals's Earnings: A Preview ↗

February 28, 2022

Xenon Pharmaceuticals (NASDAQ:XENE) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement....

Via Benzinga

Xenon Receives $15M Regulatory Milestone Under Epilepsy Pact With Neurocrine ↗

January 12, 2022

Xenon Pharmaceuticals Inc's (NASDAQ: XENE) collaboration to develop treatments for epilepsy with Neurocrine Biosciences Inc (NASDAQ: NBIX) achieved a regulatory...

Via Benzinga

Wednesdays With Wedbush: Analyst Laura Chico On The State Of Biotech ↗

December 29, 2021

For most issues in the biotech sector, it was a rough 2021, especially when compared to the gains in the S&P 500 index, Wedbush's Laura Chi...

Via Benzinga

Xenon Pharmaceuticals Scores As Epilepsy Results Highlight 'Competitive Profile' ↗

December 03, 2021

More than half of high-dose patients reported a 50% decline in monthly seizures.

Via Investor's Business Daily

Xenon Stock Jumps On New Encouraging Data From Epilepsy Treatment ↗

December 03, 2021

Xenon Pharmaceuticals Inc (NASDAQ: XENE) announced additional positive data from new sub-analyses of Phase 2b X-TOLE trial of XEN1101 in adult patients with focal...

Via Benzinga

The Daily Biotech Pulse: Protagonist Pulls Plug On Phase 1 Asset, Xenon Aces Mid-Stage Epilepsy Study, Esperion Prices Offering ↗

December 03, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Protagonist to Discontinue Development Of Early-Stage Inflammatory Diseases...

Via Benzinga

The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, & More ↗

November 28, 2021

Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant helped mitigate the losses notched earlier in the holiday-shortened week.

Via Talk Markets

The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, BeyondSpring, CTI Biopharma And Merck Take The Spotlight In A Light Calendar Week ↗

November 28, 2021

Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant, named Omicron, helped mitigate the losses...

Via Benzinga

Xenon Pharmaceuticals Has a Great Story But Too High a Price ↗

October 29, 2021

XENE stock is a valuable stock market lesson about separating great expectations for stocks from the company's true fundamentals.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For October 28, 2021 ↗

October 28, 2021

Upgrades For Boot Barn Holdings Inc (NYSE:

Via Benzinga

Xenon: Heading Toward Phase III With Strong Momentum ↗

October 26, 2021

XENE stock is on solid footing after strong trial results

Via InvestorPlace

New Clinical Results Make Xenon Pharmaceuticals’ Stock Worthy Again ↗

October 19, 2021

XENE stock deserved to move higher but was stuck for months -- until a game-changing epilepsy treatment put Xenon in the spotlight again.

Via InvestorPlace

Shares of Xenon Pharmaceuticals Inc. Have Risen Above Previous 52-Week High ↗

October 14, 2021

Shares of Xenon Pharmaceuticals Inc. (NASDAQ: XENE) traded at a new 52-week high today of $34.80. Approximately 5.5 million shares have changed hands today, as compared to an...

Via Benzinga

3 Growth Stocks Near 52-Week Highs to Buy Anyway ↗

October 14, 2021

These top performers have what it takes to keep providing outsized gains for patient investors.

Via The Motley Fool

The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage ↗

October 10, 2021

Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive stocks and into risky bets...

Via Talk Markets

The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage ↗

October 10, 2021

Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive...

Via Benzinga

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal ↗

October 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.